32960 Federal Register / Vol. 74, No. 130 / Thursday, July 9, 2009 / Notices 

manufacture of methamphetamine is as 

follows: 

(2008 APQ methamphetamine/39 

percent yield) + reserve stock ¥ 

inventory = ephedrine (for 

manufacture of methamphetamine) 

(3,130/39 percent yield) + 50 percent * 

(3,130/39 percent yield) ¥ 35 = 

12,003 kg 

The calculation for the ephedrine (for 

conversion) requirement for the 

manufacture of pseudoephedrine leads 

to a result of 106,424 kg. DEA cannot 

provide the details of the calculation 

because this would reveal the 

conversion yield for the synthesis of 

pseudoephedrine, which is proprietary 

to the one manufacturer involved in this 

type of manufacturing. 

Therefore, the assessment for 

ephedrine was determined by the sum 

total of the ephedrine (for conversion) 

requirements as described by the 

following methodology: 

methamphetamine requirement + 

pseudoephedrine requirement = 

AAN 

12,003 + 106,424 = 118,427 kg 

ephedrine (for conversion) for 2009 

This calculation suggests that based 

on applications received as of April 1, 

2009, DEA’s Assessment of Annual 

Needs for ephedrine (for conversion) 

should be established as 120,000 kg 

rather than the 110,000 kg established 

on an interim basis in the December 29, 

2008, notice. Under this rulemaking, 

DEA is establishing the Assessment of 

Annual Needs for ephedrine (for 

conversion) as 120,000 kg. 

Conclusion 

DEA has carefully considered the 

comments received in connection with 

the 2009 Assessment of Annual Needs. 

Based on information provided in the 

comments, along with information 

provided by DEA-registered 

manufacturers and importers of these 

List I chemicals on applications for 

individual import, manufacturing, and 

procurement quotas pursuant to DEA 

regulations, DEA has fully addressed the 

relevant issues set forth in the 

comments. Therefore, under the 

authority vested in the Attorney General 

by Section 306 of the CSA (21 U.S.C. 

826), and delegated to the Administrator 

of the DEA by 28 CFR Section 0.100, 

and redelegated to the Deputy 

Administrator pursuant to 28 CFR 

Section 0.104, the Deputy Administrator 

hereby orders that the 2009 Assessment 

of Annual Needs for ephedrine, 

pseudoephedrine, and 

phenylpropanolamine, expressed in 

kilograms of anhydrous acid or base, be 

established as follows: 

List I chemical 

Established 

2009 

Assessment of 

Annual Needs 

Ephedrine (for sale) .............. 3,400 

Ephedrine (for conversion) ... 120,000 

Pseudoephedrine (for sale) .. 390,000 

Phenylpropanolamine (for 

sale) .................................. 4,900 

Phenylpropanolamine (for 

conversion) ........................ 62,000 

The Office of Management and Budget 

has determined that notices of quotas 

are not subject to centralized review 

under Executive Order 12866. 

This action does not preempt or 

modify any provision of state law; nor 

does it impose enforcement 

responsibilities on any state; nor does it 

diminish the power of any state to 

enforce its own laws. Accordingly, this 

action does not have any federalism 

implications warranting the application 

of Executive Order 13132. 

The Deputy Administrator hereby 

certifies that this action will not have a 

significant economic impact upon a 

substantial number of small entities 

whose interests must be considered 

under the Regulatory Flexibility Act, 5 

U.S.C. 601–612. The establishment of 

Assessment of Annual Needs for 

ephedrine, pseudoephedrine, and 

phenylpropanolamine is mandated by 

law. The assessments are necessary to 

provide for the estimated medical, 

scientific, research and industrial needs 

of the United States; for lawful export 

requirements; and the establishment 

and maintenance of reserve stocks. 

Accordingly, the Deputy Administrator 

has determined that this action does not 

require a regulatory flexibility analysis. 

This action meets the applicable 

standards set forth in Sections 3(a) and 

3(b)(2) of Executive Order 12988 Civil 

Justice Reform. 

This action will not result in the 

expenditure by state, local, and tribal 

governments, in the aggregate, or by the 

private sector, of $120,000,000 or more 

(adjusted for inflation) in any one year, 

and will not significantly or uniquely 

affect small governments. Therefore, no 

actions were deemed necessary under 

the provisions of the Unfunded 

Mandates Reform Act of 1995. 

This action is not a major rule as 

defined by Section 804 of the Small 

Business Regulatory Enforcement 

Fairness Act of 1996 (Congressional 

Review Act). This action will not result 

in an annual effect on the economy of 

$100,000,000 or more; a major increase 

in costs or prices; or significant adverse 

effects on competition, employment, 

investment, productivity, innovation, or 

on the ability of United States-based 

companies to compete with foreignbased companies in domestic and 

export markets. 

Dated: June 26, 2009. 

Michele M. Leonhart, 

Deputy Administrator. 

[FR Doc. E9–16152 Filed 7–8–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated June 7, 2007, and 

published in the Federal Register on 

June 20, 2007, 72 FR 34040, Cambrex 

Charles City, Inc., 1205 11th Street, 

Charles City, Iowa 50616–3466, made 

application by letter to the Drug 

Enforcement Administration (DEA) to 

be registered as an importer of the basic 

classes of controlled substances listed in 

schedule II: 

Drug Schedule 

Opium, raw (9600) ........................ II 

Poppy Straw Concentrate (9670) II 

The company plans to import the 

basic classes of controlled substances 

for manufacture of active 

pharmaceutical ingredients for sale to 

its customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a) 

and determined that the registration of 

Cambrex Charles City, Inc. to import the 

basic classes of controlled substances is 

consistent with the public interest and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971, at 

this time. DEA has investigated 

Cambrex Charles City, Inc. to ensure 

that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic classes of controlled 

substances listed. 


rmajette on DSK29S0YB1 with NOTICES
Federal Register / Vol. 74, No. 130 / Thursday, July 9, 2009 / Notices 32961 

Dated: June 24, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–16295 Filed 7–8–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated June 26, 2007, and 

published in the Federal Register on 

July 3, 2007 (72 FR 36481), Johnson 

Matthey Inc., Pharmaceutical Materials, 

2003 Nolte Drive, West Deptford, New 

Jersey 08066, made application by letter 

to the Drug Enforcement Administration 

(DEA) to be registered as an importer of 

Coca Leaves (9040), a basic class of 

controlled substance listed in schedule 

II. 

The company plans to import the 

listed controlled substance to 

manufacture bulk Cocaine HCL for sale 

to finished dosage form manufacturers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a) 

and determined that the registration of 

Johnson Matthey Inc. to import the basic 

class of controlled substance is 

consistent with the public interest and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971, at 

this time. DEA has investigated Johnson 

Matthey Inc. to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic class of controlled substance 

listed. 

Dated: June 24, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–16293 Filed 7–8–09; 8:45 am] 

BILLING CODE 4410–09–P 

NATIONAL AERONAUTICS AND 

SPACE ADMINISTRATION 

[Notice (09–063)] 

NASA Advisory Council; Science 

Committee; Heliophysics 

Subcommittee; Meeting 

AGENCY: National Aeronautics and 

Space Administration. 

ACTION: Notice of meeting. 

SUMMARY: The National Aeronautics and 

Space Administration (NASA) 

announces a meeting of the 

Heliophysics Subcommittee of the 

NASA Advisory Council (NAC). This 

Subcommittee reports to the Science 

Committee of the NAC. The Meeting 

will be held for the purpose of soliciting 

from the scientific community and other 

persons scientific and technical 

information relevant to program 

planning. 

DATES: Monday, July 13, 2009, 8:30 a.m. 

to 5 p.m., and Tuesday, July 14, 2009, 

8:30 a.m. to 5 p.m. Eastern Daylight 

Time. 

ADDRESSES: L’Enfant Plaza Hotel, Renoir 

Room, 480 L’Enfant Plaza, SW., 

Washington, DC 20024. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Marian Norris, Science Mission 

Directorate, NASA Headquarters, 

Washington, DC 20546, (202) 358–4452, 

fax (202) 358–4118, or 

mnorris@nasa.gov. 

SUPPLEMENTARY INFORMATION: The 

meeting will be open to the public up 

to the capacity of the room. The agenda 

for the meeting includes the following 

topics: 

—Heliophysics Division Overview and 

Program Status; 

—Annual Review of Heliophysics 

Science Performance for Fiscal Year 

2009; 

—Status of Proposed Revision to 

Heliophysics Data Policy; 

—Discussion of Decadal Survey 

Assessment and NASA Response; 

—Update on Interagency Planning for 

Space Weather Monitor at the L1 

Libration Point. 

It is imperative that the meeting be 

held on these dates to accommodate the 

scheduling priorities of the key 

participants. Attendees will be 

requested to sign a register. For future 

information, you may contact Marian 

Norris via e-mail at mnorris@nasa.gov or 

by telephone at (202) 358–4452. 

P. Diane Rausch, 

Advisory Committee Management Officer, 

National Aeronautics and Space 

Administration. 

[FR Doc. E9–16215 Filed 7–8–09; 8:45 am] 

BILLING CODE 7510–13–P 

NATIONAL SCIENCE FOUNDATION 

Agency Information Collection 

Activities: Comment Request 

AGENCY: National Science Foundation. 

ACTION: Submission for OMB review; 

comment request. 

SUMMARY: The National Science 

Foundation (NSF) has submitted the 

following information collection 

requirement to OMB for review and 

clearance under the Paperwork 

Reduction Act of 1995, Public Law 104– 

13. This is the second notice for public 

comment; the first was published in the 

Federal Register at 74 FR 13270, and no 

comments were received. NSF is 

forwarding the proposed renewal 

submission to the Office of Management 

and Budget (OMB) for clearance 

simultaneously with the publication of 

this second notice. The full submission 

may be found at: http:// 

www.reginfo.gov/public/do/PRAMain. 

Comments regarding (a) Whether the 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; (b) the accuracy of the 

agency’s estimate of burden including 

the validity of the methodology and 

assumptions used; (c) ways to enhance 

the quality, utility and clarity of the 

information to be collected; or (d) ways 

to minimize the burden of the collection 

of information on those who are to 

respond, including through the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology should be 

addressed to: Office of Information and 

Regulatory Affairs of OMB, Attention: 

Desk Officer for National Science 

Foundation, 725—17th Street, NW., 

Room 10235, Washington, DC 20503, 

and to Suzanne H. Plimpton, Reports 

Clearance Officer, National Science 

Foundation, 4201 Wilson Boulevard, 

Suite 295, Arlington, Virginia 22230 or 

send e-mail to splimpto@nsf.gov. 

Comments regarding this information 

collection are best assured of having 

their full effect if received within 30 

days of this notification. Copies of the 


rmajette on DSK29S0YB1 with NOTICES